ArticleJournal of clinical microbiology2020
Evaluation of Commercial Molecular Diagnostic Methods for Detection and Determination of Macrolide Resistance in Mycoplasma pneumoniae.
Article in Journal of clinical microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Mapping the Evolution of Diagnostic Research onPathogens (Basel, Switzerland) · 2026Review
- Exploiting the Clinical Potential of a Chemiluminescent Probe forChemical & biomedical imaging · 2026Article
- Clinical performance of two commercial PCR assays for the detection of macrolide resistance inJournal of clinical microbiology · 2026Article
- Article
- Association between 25-hydroxy vitamin D, interleukin-4, and interferon-γ levels and asthma in children with Mycoplasma pneumonia infection.Scientific reports · 2024Article
- Comparison of Real-time Polymerase Chain Reaction and Culture for Targeting Pathogens in Pediatric Severe Community-Acquired Pneumonia.Turkish archives of pediatrics · 2024Article
- Effectiveness of the six-step approach guided online training program to improve knowledge ofTranslational pediatrics · 2024Article
- An accurate and convenient method forFrontiers in cellular and infection microbiology · 2024Article
- A comprehensive review ofFrontiers in medicine · 2024Review
- Absolute quantification ofFrontiers in microbiology · 2023Article
- Case Report: Omadacycline in the treatment of macrolide-unresponsiveFrontiers in cellular and infection microbiology · 2023Article
- Review
- Development of a Rapid and Efficient RPA-CRISPR/Cas12a Assay forFrontiers in microbiology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 10 institutions in 1 country.
Funding
Abstract
We evaluated six commercial molecular tests targeting
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.